Testing the Feasibility of a Passive and Active Case Ascertainment System for Multiple Rare Conditions Simultaneously: The Experience in Three US States

Amanda Reichard
*University of New Hampshire, Durham*

Suzanne McDermott
*University of South Carolina - Columbia*

Margaret Ruttenber
*Colorado Department of Public Health and Environment*

Joshua Mann
*University of Mississippi Medical Center*

Michael G. Smith

*See next page for additional authors*

Follow this and additional works at: https://scholars.unh.edu/iod_chhs

**Recommended Citation**
Reichard A, McDermott S, Ruttenber M, Mann J, Smith MG, Royer J, Valdez R Testing the Feasibility of a Passive and Active Case Ascertainment System for Multiple Rare Conditions Simultaneously: The Experience in Three US States JMIR Public Health Surveill 2016;2(2):e151 https://dx.doi.org/10.2196/publichealth.5516

This Article is brought to you for free and open access by the College of Health & Human Services (CHHS) at University of New Hampshire Scholars' Repository. It has been accepted for inclusion in Institute on Disability by an authorized administrator of University of New Hampshire Scholars' Repository. For more information, please contact Scholarly.Communication@unh.edu.
Authors
Amanda Reichard, Suzanne McDermott, Margaret Ruttenber, Joshua Mann, Michael G. Smith, Julie Royer, and Rodolfo Valdez

This article is available at University of New Hampshire Scholars' Repository: https://scholars.unh.edu/iod_chhs/38
Testing the Feasibility of a Passive and Active Case Ascertainment System for Multiple Rare Conditions Simultaneously: The Experience in Three US States

Amanda Reichard1, PhD; Suzanne McDermott2, PhD; Margaret Ruttenber3, MSPH; Joshua Mann4, MD; Michael G Smith5, DrPH; Julie Royer6, MSPH; Rodolfo Valdez7, MSc, PhD

1Institute on Disability, University of New Hampshire, Durham, NH, United States
2Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, United States
3Special Health Care Needs, Colorado Department of Public Health and Environment, Denver, CO, United States
4Department of Preventive Medicine, University of Mississippi Medical Center, Jackson, MS, United States
5South Carolina Department of Health and Environmental Control, Columbia, SC, United States
6Revenue and Fiscal Affairs Office, South Carolina Budget and Control, Columbia, SC, United States
7National Center for Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, United States

Corresponding Author:
Amanda Reichard, PhD
Institute on Disability
University of New Hampshire
10 West Edge Dr, Suite 101
Durham, NH, 03824
United States
Phone: 1 603 862 5266
Fax: 1 603 862 0555
Email: amanda.reichard@unh.edu

Abstract

Background: Owing to their low prevalence, single rare conditions are difficult to monitor through current state passive and active case ascertainment systems. However, such monitoring is important because, as a group, rare conditions have great impact on the health of affected individuals and the well-being of their caregivers. A viable approach could be to conduct passive and active case ascertainment of several rare conditions simultaneously. This is a report about the feasibility of such an approach.

Objective: To test the feasibility of a case ascertainment system with passive and active components aimed at monitoring 3 rare conditions simultaneously in 3 states of the United States (Colorado, Kansas, and South Carolina). The 3 conditions are spina bifida, muscular dystrophy, and fragile X syndrome.

Methods: Teams from each state evaluated the possibility of using current or modified versions of their local passive and active case ascertainment systems and datasets to monitor the 3 conditions. Together, these teams established the case definitions and selected the variables and the abstraction tools for the active case ascertainment approach. After testing the ability of their local passive and active case ascertainment system to capture all 3 conditions, the next steps were to report the number of cases detected actively and passively for each condition, to list the local barriers against the combined passive and active case ascertainment system, and to describe the experiences in trying to overcome these barriers.

Results: During the test period, the team from South Carolina was able to collect data on all 3 conditions simultaneously for all ages. The Colorado team was also able to collect data on all 3 conditions but, because of age restrictions in its passive and active case ascertainment system, it was able to report few cases of fragile X syndrome. The team from Kansas was able to collect data only on spina bifida. For all states, the implementation of an active component of the ascertainment system was problematic. The passive component appears viable with minor modifications.

Conclusions: Despite evident barriers, the joint passive and active case ascertainment of rare disorders using modified existing surveillance systems and datasets seems feasible, especially for systems that rely on passive case ascertainment.

(JMIR Public Health Surveill 2016;2(2):e151) doi:10.2196/publichealth.5516

http://publichealth.jmir.org/2016/2/e151/
KEYWORDS
spina bifida; muscular dystrophy; fragile X syndrome; surveillance

Introduction

Methods for Surveillance of Rare Conditions
Surveillance is used to gather data and knowledge that can be used to identify and control a health problem or to improve a public health program or service [1]. Birth defects monitoring programs, which focus primarily on identifying diagnosed cases, have widely used passive systems that gather data from administrative data such as hospital discharge records and administrative records from public insurers [2]. However, these systems can both over- and underestimate the actual prevalence of conditions, because coding for billing purposes is not always accurate or complete [3-5].

Active case ascertainment methods are considered the “gold standard” in public health surveillance [6]. These methods involve trained coders collecting data directly from medical providers, health service providers, and educational institutions to identify cases. The biggest challenge for using these methods is locating people with any of the conditions of interest within a designated geographic area [7]. Thus, population-based approaches must actively review records from diverse sources (eg, inpatient and outpatient settings, rehabilitation services, disability-specific programs, schools) [8].

Rare conditions such as spina bifida, fragile X syndrome, and muscular dystrophy can be especially difficult to monitor. Among these 3 conditions, only spina bifida is recognizable at birth and more easily included in state-based birth defects monitoring systems. The other 2 conditions—fragile X syndrome and muscular dystrophy—are not apparent in the early days of life and no laboratory test or biomarker is commonly used to screen newborns for these conditions. Instead, fragile X syndrome and muscular dystrophy are often identified during early childhood after parents and primary care providers note developmental or motor deficits. Both conditions require specific genetic tests to confirm their diagnosis; however, this usually occurs in an outpatient setting and does not require hospitalization. Thus, the data sources for passive surveillance of these conditions need to be extended not only to genetic laboratories but also to specialty care clinics where diagnosis is confirmed typically after multiple visits [9-11].

Spina Bifida
Spina bifida occurs when the neural tube fails to close properly during fetal development [12-14]. The incidence of spina bifida detected at birth (namely, meningocele and myelomeningocele) decreased from approximately 2.5/10,000 (95% CI 2.3-2.7) in 1992 to 2.0/10,000 (95% CI 1.9-2.1) in 2001. The National Birth Defects Prevention Network estimated the prevalence of spina bifida (without hydrocephaly) was 3.5/10,000 live births (95% CI 3.31-3.68) [14].

Muscular Dystrophy
Muscular dystrophies are a group of genetic diseases characterized by progressive skeletal muscle degeneration and weakness [15]. Although more than 30 forms of muscular dystrophy have been identified, there are 9 major forms [16]. The most common muscular dystrophies, Duchenne muscular dystrophy and Becker muscular dystrophy, together have an estimated prevalence of 1.38/10,000 males aged 5 to 24 years [16]. Other major forms (eg, distal, Emery-Dreifuss) each have a prevalence of 1 to 2 per 100,000 [17,18].

Fragile X Syndrome
Fragile X syndrome results from a mutation in the fragile X mental retardation 1 gene, FMR1, on the X chromosome [19]. Impairment severity can range from relatively mild learning disabilities to moderate intellectual disability and autism or “autistic-like” behaviors. Approximately 1 in 3600 to 4000 males and 1 in 4000 to 6000 females is born with the full mutation for fragile X. The vast majority of males and about 50% of females with the full mutation will have fragile X syndrome [19-21].

Importance of Surveillance of These 3 Rare Conditions
These conditions have low prevalence but a great impact on long-term disability, mortality, cost, and caregiver stress [12,22,23]. Obtaining a better estimate of state prevalence is a necessary starting point for assessing the impact. Such tracking requires the following: a flexible population scope (eg, specific to infants and young children); expansion of data sources (eg, health care specialists and tertiary medical centers); and labor-intensiveness (eg, data abstracted from a large number of health care practices).

Spina bifida, muscular dystrophy, and fragile X syndrome were chosen for this feasibility study because (1) they are all low incidence conditions with high health and economic impact; (2) they encompass a wide range of etiological, physical, and cognitive symptoms; (3) they represent various degrees of difficulty for passive and active case ascertainment; (4) public and private organizations have long-standing active research programs and data collections on these 3 conditions; and (5) the US Congress has provided special funding to monitor and study these 3 conditions [24-27].

The low prevalence of rare disorders makes impractical the development of a separate passive and active case ascertainment system for each condition but lends itself to a combined case ascertainment system that would monitor several conditions at once. Such an integrated passive and active case ascertainment system could serve as a model for other low prevalence and high-impact conditions. Simultaneous passive and active case ascertainment of rare conditions may lead to public health interventions that improve the health of a sizable segment of the population affected by these conditions. Thus, the purpose of this paper is to report on the feasibility of developing a rare conditions passive and active case ascertainment system that simultaneously monitors spina bifida, muscular dystrophy, and fragile X syndrome within a state. In each of the 3 states in which this work was undertaken, objectives were to (1) assess the ability of the local passive and active case ascertainment systems to capture the 3 rare disorders, (2) capture preliminary...
state prevalence estimates of the conditions, and (3) discover barriers and facilitators to such implementation. Findings can provide lessons for future rare conditions passive and active case ascertainment activities in states with similar systems to these.

Methods

Justification of States Included in the Study

The design of this feasibility study required that the states included were at varying levels of readiness toward implementing a rare conditions passive and active case ascertainment program. The state teams were selected by the study team, based on knowledge of states with disability epidemiologists and their understanding of data capability. States were also selected so that they roughly conformed to one each on the high, medium, and lower levels of passive and active case ascertainment sophistication. Colorado (high) and South Carolina (medium) were selected because of their established and state-supported birth defects passive and active case ascertainment system and, in the case of South Carolina, other integrated data system capacities. Kansas (low) was selected because it was home to a disability epidemiologist who had published articles using the Medicaid system to analyze disability and health issues. The approach in each state was to identify existing passive and active case ascertainment systems and data sources that could be expanded to implement a more comprehensive system within 2 years. The 2-year duration was chosen to allow up to 1 year for the assessment of current passive and active case ascertainment systems, standardization of case definitions, and selection of variables for the active case ascertainment component; and an additional year to test the feasibility of modestly enlarging the existing systems to assess what is feasible and to compare the three systems. Within each state, systems were compared by (1) using data from the active system to assess the accuracy of cases identified in the passive system and (2) capture-recapture methodology to get estimates of the prevalence of the 3 conditions.

The first step was to document how states varied in their different resources, approaches, and levels of experience in conducting passive and active case ascertainment. Table 1 compares passive and active case ascertainment programs in the 3 states [28,29]. The same sources and variables were searched and assessed for all 3 conditions.

Colorado has a mature, state-mandated, birth defects surveillance system in the health department, which requires reporting up to age 3 years. This system conducts active case finding through administrative data sources and it includes reports of spina bifida that mirror expected prevalence. Colorado also has a Centers for Disease Control and Prevention (CDC)–funded muscular dystrophy surveillance program (Muscular Dystrophy Surveillance, Tracking, and Research Network; MD STARNet) that uses active surveillance in neuromuscular clinics to identify childhood-onset cases. The MD STARNet system had been ongoing for 10 years at the beginning of our project. The challenge for Colorado was to identify cases of fragile X syndrome, because there had only been a few cases reported in the past decade. Fragile X syndrome is an inherited cause of intellectual disability, which is not apparent at birth. When intellectual disability is diagnosed in a child, a genetic diagnostic examination is needed to make the fragile x syndrome diagnosis; thus, in many cases this is not done before the child’s third birthday. The fact that Colorado only had a few cases of fragile X syndrome reported before the onset of the project suggests that even established birth defects systems need expanded authority through their legislature to collect information about people who are older than 3 years. The Colorado passive and active case ascertainment system needs to pursue sources of reporting, such as the fragile X clinic in their state, if they want to conduct passive and active case ascertainment of rare conditions. South Carolina has a birth defects case ascertainment system that relies on active hospital record abstraction for spina bifida and other early identifiable birth defects. This system had been collecting cases of spina bifida at the prevalence rate that was expected. South Carolina also has a well-established administrative data system that allows linkage among a large number of public insurance, vital records, and state service agency secondary data sources. This system was available for passive ascertainment. The South Carolina project developed an active surveillance system in 5 counties to compare the active and passive ascertainment of the 3 conditions. Kansas, likewise, has a birth defects surveillance system housed in the health department that primarily relied on birth certificate reporting of birth defects. This system has a passive case ascertainment component and no active case ascertainment component. Thus, the challenge for Kansas was to develop a small, active, case ascertainment component for this project.

During the first year of this 2-year project the teams from Colorado and South Carolina began with the identification of existing data sources. The Kansas team spent the first year cataloging features they could use from the other 2 states that had well-developed passive and active case ascertainment systems, investigating the capacity of local chapters of parent advocacy organizations for each condition, and conducting an extensive literature review. The Kansas team worked with the South Carolina and Colorado health departments to obtain information about policies and procedures related to existing passive and active case ascertainment systems, particularly on birth defects monitoring programs.

Together, the teams from the 3 states established uniform case definitions (including International Classification of Diseases, Ninth Revision, or ICD-9 codes and other required elements), variable definitions, and data abstraction tools for the active case ascertainment approach. The codes used in the 3 states are listed in Table 2. South Carolina and Kansas completed institutional review board (IRB) reviews that were needed because an active case ascertainment system that covered all ages was being used for this project, and this expanded an existing state statutory system.
Table 1. Major characteristics of the case ascertainment system in 3 US states.

| Characteristics                                                                 | Colorado                                      | South Carolina                                      | Kansas                                        |
|---------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------|-----------------------------------------------|
| **State characteristics**                                                        |                                               |                                                    |                                               |
| Legislative authority                                                            | CRS\(^a\) 25-1.5-101 to 25-1.5-105; enacted in 1985 | A281,R308,H4115; enacted in 2004                     | KSA\(^b\) 65-1241 to 65-1246; enacted in 2004 |
| Location                                                                        | Department of Health: Epidemiology and Environment | Department of Health: Maternal and Child Health    | Department of Health: Vital Statistics, Maternal and Child Health |
| Characterization of the passive and active case ascertainment system            | Mostly passive                                | Passive and active                                  | Passive only                                  |
| **Data characteristics**                                                         |                                               |                                                    |                                               |
| Data sources                                                                     | Case ascertainment (active, passive); vital records (birth, death, and fetal death certificates); state-based registries; delivery hospitals; tertiary care hospitals; genetic counseling services; genetic clinics; physician reports. | Case ascertainment (active); vital records (birth, death, fetal death, and elective termination certificates); state-based registries; delivery hospitals; tertiary care hospitals; prenatal diagnosis facilities; genetic laboratories; genetic counseling services; genetic clinics; physician reports; passive sources; Medicaid; hospital discharges; state health plan claims; Department of Disabilities and Special Needs. | Case ascertainment (passive); vital records (birth and fetal death certificates); state-based registries; physician reports. |
| Time frame—years covered for passive case ascertainment                          | SB\(^c\): 2010-12                              | SB: 1996-2012                                      | SB: 1979-2013                                 |
|                                                                                  | MD\(^d\): 1992-2011                             | MD: 1996-2012                                      |                                               |
|                                                                                  | FXS\(^e\): 2007-12                              | FXS: 1996-2012 (secondary data with code)          |                                               |
| Time frame—years covered for active case ascertainment                           | SB: 2010-12                                    | SB: 2013-2014                                      | SB: 1971-2013                                 |
|                                                                                  | MD: 1992-2011                                  | MD: 2013-2014                                      |                                               |
|                                                                                  | FXS: 2007-12                                   | FXS: 2013-2014 (for prevalent cases)               |                                               |
| Age range covered, years                                                         | 0-3 (SB, FXS); 0-28 (MD)                       | No limit                                           | No limit                                      |
| Data sources for the active case ascertainment component in this project         | Reascertainment and medical records.            | Medical records (5 counties).                      | Medical records (1 county).                   |
| Clinical review for the passive component of this project                       | Yes                                            | No                                                 | No                                            |
| Clinical review for the active component of this project                        | Yes                                            | Yes                                                | Yes                                           |
| Barriers to implementation                                                       | Not enough time to change the age of reporting FXS from 3 to 10 years. | The active component could be labor intensive.     | Limited availability and interconnection of data sources. |

\(^a\)CRS: Colorado Revised Statutes.  
\(^b\)KSA: Kansas Statutes Annotated.  
\(^c\)SB: spina bifida.  
\(^d\)MD: muscular dystrophy.  
\(^e\)FXS: fragile X syndrome.
Colorado Responds to Children with Special Needs (CRCSN) has developed a multistep approach to monitor data sources, specific diagnoses, over- and under-ascertainment, and transitional computer program that prepared the case for further processing before being posted to a core database. All case reports went through an extensive search and/or match process that linked cases to a unique identifier.

Colorado has participated in a number of CDC-funded surveillance efforts that have enhanced its data collection processes. For example, CRCSN collected data on children with spina bifida up to age 3 years through the CDC-funded Rapid Ascertaining project that uses a passive registry followed by a reascertainment and medical record review as confirmation for all live births [30]. Colorado has also participated in the CDC-funded MD STARnet program since it began surveillance for Duchenne and Becker muscular dystrophies in 2002 [31]. Recently, MD STARnet was expanded to include 7 additional types of muscular dystrophy. CRCSN has collected information on fragile X syndrome since 1994, through its passive Birth Defects Monitoring system, but only a few cases were reported in recent years. As part of this feasibility passive and active case ascertainment effort the Colorado project staff met with the director of the fragile X clinic at Children’s Hospital Colorado in an effort to expand the passive ascertainment and explore the possibility of conducting a medical record review to identify persons for whom a genetics laboratory confirmation was available. This contact was necessary to inform the director of the clinic’s responsibility to report children younger than 3 years with fragile X syndrome to the CRCSN system.

### Colorado’s Approach to Active Case Ascertainment of Persons With Fragile X Syndrome, Spina Bifida, and Muscular Dystrophy

The CRCSN staff established specific guidelines for each case definition, which required the number of times a diagnosis is reported, the number of reporting sources, and the use of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes. The CRCSN did not implement an active case ascertainment system per se; instead, it supplemented the passive system with rigorous reascertainties and medical record reviews by physicians of all spina bifida cases and some muscular dystrophy cases. Before this feasibility project, this approach was not used for cases of fragile X syndrome.

CRCSN has developed a multistep approach to monitor data sources, specific diagnoses, over- and under-ascertainment, and

---

**Table 2.** Diagnosis codes and variables used to passively identify cases in a pilot project for a 3-state (Colorado, Kansas, South Carolina) public health passive and active case ascertainment system for 3 rare conditions (spina bifida, muscular dystrophy, and fragile X syndrome).

| Condition                                      | Hospital discharge and insurance                      | Birth certificates                      | Death certificates                |
|------------------------------------------------|-------------------------------------------------------|----------------------------------------|----------------------------------|
| Fragile X syndrome                            | 759.83 ICD-9-CM                                      | N/A a                                 | Q99.2                            |
| Muscular dystrophy                            | 359.0, 359.1, and 359.21 ICD-10 b                     | N/A b                                 | G71.0 and G71.1                  |
| Spina bifida (without anencephalies)          | 741.0 through 741.9 ICD-9-CM                         | Myelomeningocele or meningocoele variable | Q05 including Q05.0 to Q05.9    |

---

aICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification.
bICD-10: International Classification of Diseases, Tenth Revision.
cN/A: not applicable.
problematic code assignment issues. Its data quality validation procedure includes computerized and manual approaches (computer screen review of case records, medical records review of selected cases, and clinical consultation when difficulties were identified). Additionally, two levels of clinical reviews are used for diagnosis: (1) staff level (to identify problems in report date, source of diagnosis, site of the encounter, and ICD-9-CM codes); (2) medical specialist level (to review the medical records and other relevant information to verify the diagnosis).

**South Carolina**

In this state, faculty from the University of South Carolina School of Public Health and the Medical University of South Carolina partnered with the South Carolina Department of Health and Environmental Control (DHEC) to complete this project. The active case ascertainment was conducted by the DHEC and the data utilized for the passive case ascertainment system was housed within the Revenue and Fiscal Affairs (RFA) agency. The RFA has agreements with state agencies and organizations to store data, although each data source retains control of the data at all times. Thus, RFA facilitated the development of written agreements with each agency and organization that potentially had data elements that could be used for this project. For unidentified data projects, including this rare conditions passive and active case ascertainment effort, the RFA uses an algorithm that relies on source-specific personal identifiers to create a global unique identifier. The data are edited and standardized before being run through the search algorithm. The global unique identifier is not associated with any personal identifier and is used on all subsequent episodes of services, regardless of data source or service provider. Using the unique global identifier enables staff to use data across multiple providers while protecting confidentiality. The investigators of the rare conditions passive and active case ascertainment system included one RFA staff member, a health department investigator, and university investigators.

**South Carolina’s Approach to Passive Case Ascertainment of Persons With Fragile X Syndrome, Spina Bifida, and Muscular Dystrophy**

All persons with an ICD-9-CM primary or secondary diagnosis code for fragile X syndrome, spina bifida, or muscular dystrophy were identified from Medicaid, the Hospital Discharge Dataset, and the claims from the State Health Plan that insures all government workers and their families (Table 2). The South Carolina DHEC Birth Defects Monitoring Program was used to identify cases of spina bifida. For all 3 conditions, death certificate records were used to identify unique cases from previous periods. These cases occur if people received care out of state or if they did not have their condition diagnosis included when they were seen in the medical care system. These cases were identified by International Classification of Diseases, Tenth Revision, (ICD-10) cause-of-death codes for fragile X syndrome, spina bifida, and muscular dystrophy from the South Carolina DHEC. For fragile X syndrome and muscular dystrophy, South Carolina also identified cases through the Department of Disabilities and Special Needs, the agency that provides support and services to people with disability.

**South Carolina’s Approach to Active Case Ascertainment of Persons With Fragile X Syndrome, Spina Bifida, and Muscular Dystrophy**

South Carolina DHEC established an active case ascertainment component for citizens of all ages with rare conditions in 5 South Carolina counties for this project, after IRB approval. After cases were reported to the South Carolina DHEC Birth Defects Monitoring Program by the physician practices, a registered nurse abstractor traveled to each practice to abstract relevant data (ie, basic diagnosis and demographic information; sufficient but less rigorous than the Colorado MD STARnet protocol for muscular dystrophy) from medical records of those who had received treatment in a clinic, hospital, or practice located in those 5 counties. The data were then entered into an Epi Info [32] data system for compilation, output into an SAS [33] file for editing, linking with passive data, and analysis.

**South Carolina’s Approach to Merging the Passive and Active Systems**

At the conclusion of active data collection for the 5 designated counties, the data from the passive case ascertainment system and the active case ascertainment system were linked and analyzed at RFA. The data collected through the passive system were compared with the data from the active case ascertainment system to test the accuracy and completeness of the passive system. Non-RFA investigators were provided with aggregate reports.

**Kansas**

Congenital anomalies have been recorded in Kansas birth certificates since 1979 and since 1982, Kansas has had, under administrative regulations, a limited set of passive case ascertainment activities for these anomalies [28]. In 2004, the Kansas legislature issued the statutes for the creation of the Birth Defects Information System (BDIS) with the aim of collecting information on congenital anomalies and other birth abnormalities among children younger than 5 years [28]. Currently, the BDIS includes an interface between a birth defects database and a Web-based application from the program Children and Youth with Special Health Care Needs, along with relevant variables from the Vital Statistics Integrated Information System. Thirteen anomalies are currently listed in the birth certificates and reported to the BDIS [28].

**Kansas’ Approach to Passive Case Ascertainment for Persons With Fragile X Syndrome, Spina Bifida, and Muscular Dystrophy**

Given the strong reliance of the BDIS on birth certificates and because spina bifida is the only one of the 3 conditions included in this report that is diagnosed at birth, the Kansas team developed a passive case ascertainment plan just for spina bifida. First, the team identified cases of spina bifida using ICD-9-CM codes (see Table 2) in a Medicaid claims database. Then, relevant individual information from these cases was merged with individual information from the BDIS. Finally, the individual data were deduplicated and aggregated to obtain the count of spina bifida cases in the state.
Kansas’ Approach to Active Case Ascertainment for Persons With Fragile X Syndrome, Spina Bifida, and Muscular Dystrophy

For the active case ascertainment component, the Kansas team mailed a letter to pediatricians, neurologists, and spina bifida clinics in one county (Sedgwick) in Kansas asking them to report all of their cases of spina bifida, under authority of the Kansas Birth Defects Act (KSA 65-1241 through 65-1246). Sedgwick County, including the city of Wichita, is a large county, including 17.5% of the state’s total population [34]. For professional medical record abstraction, eligible medical records were sent to the Kansas Foundation for Medical Care (KFMC), a state not-for-profit organization that has served as the state’s External Quality Review Organization and information technology resource in the state. Additionally, KFMC provided advice on data aggregation.

Kansas’ Approach to Merging the Passive and the Active Case Ascertainment Systems

When the active component of the project was completed, KFMC shared the active case ascertainment dataset with the Kansas team. These data were merged with the passive dataset to identify the cases that were common between both datasets.

Results

Findings by State

Within the 2-year period allocated to this project, the South Carolina team was able to use the passive and active case ascertainment capabilities of the state to assemble a passive and active case ascertainment system, with both passive and active components, to simultaneously detect spina bifida, muscular dystrophy, and fragile X syndrome. The active component of the South Carolina team, however, was limited to 5 counties. The Colorado team supplemented their extensive passive system with reascertainment and clinical review of the cases; however, because of age restrictions in reporting, this team was able to detect only a handful of cases of fragile X syndrome. The Kansas team was able to assemble a case ascertainment system with passive and active components, but only for 1 condition, spina bifida, and the active component of this system was limited to 1 county.

On the basis of cases found, the teams calculated number and prevalence for their respective states. These estimates are tentative, not comparable in any way from one state to the other, and certainly not comparable to published estimates calculated with more rigorous methods. Table 3 presents the data collected in the 3 states, collected for spina bifida, muscular dystrophy, and fragile X syndrome. The racial composition of cases in the 3 states differed substantially, but this composition follows the underlying population of each state. In 2014, a total of 66% of the South Carolina population was white, 27% black, and 5% Hispanic, and the cases of spina bifida and muscular dystrophy reflect this pattern. The cases of fragile X syndrome are 47% white for active and 54% for passive. In Colorado and Kansas, there were high proportions of missing data or “other” racial groups noted. The male to female ratio for spina bifida was not consistent across the 3 areas. More females than males were identified in South Carolina and more males than females were identified in both Colorado and Kansas. The higher proportion of male cases identified with muscular dystrophy and fragile X syndrome in Colorado and South Carolina (muscular dystrophy only) reflects the fact that these 2 conditions have genetic X-linked inheritance.

Table 4 presents the rates of spina bifida, muscular dystrophy, and fragile X syndrome identified in this pilot project. In Colorado, the rate for spina bifida was 3.35/10,000 for those younger than 3 years, for muscular dystrophy the rate was 1.29/10,000, and with only 6 identified cases of fragile X syndrome the rate was close to zero. The passive and active case ascertainment efforts in South Carolina were for all ages, so the denominator for South Carolina was the state population for passive case ascertainment and the all age population of 5 counties around the metropolitan areas of Columbia and Charleston for active case ascertainment. The South Carolina passive rates were substantially higher than active rates for spina bifida (2.16/10,000 for active and 12.15/10,000 for passive) and muscular dystrophy (3.28/10,000 for active and 6.84/10,000 for passive). For fragile X syndrome these rates were more similar, 1.20/10,000 for active and 1.65/10,000 for passive case ascertainment. In Kansas, for the one county used for active case ascertainment of spina bifida the rate was 0.86/10,000 and the passive rate was 3.04/10,000.
Table 3. Summary of data collected in a pilot project for a 3-state (Colorado, Kansas, South Carolina) public health passive and active case ascertainment system for 3 rare conditions (spina bifida, muscular dystrophy, and fragile X syndrome).

| Condition                  | Colorado\(^a\) (64 counties) n (%) | South Carolina active (5 counties) n (%) | South Carolina passive (46 counties) n (%) | Kansas active (1 county) n (%) | Kansas passive (statewide) n (%) |
|----------------------------|------------------------------------|-----------------------------------------|---------------------------------------------|-------------------------------|----------------------------------|
| Spina bifida, N            | ...                                | 253                                     | 5872                                        | ...                           | 882                              |
| Non-Hispanic black         | ...                                | 73 (28.8)                               | 1590 (27.1)                                 | ...                           | 25 (2.8)                         |
| Non-Hispanic white         | 30 (...)                           | 138 (54.5)                              | 3628 (61.8)                                 | 21 (...)                      | 296 (33.6)                      |
| Hispanic and others        | 28 (...)                           | 42 (16.6)                               | 654 (11.1)                                  | 19 (...)                      | 561 (63.6)                      |
| Male                       | 36 (61.0)                          | 112 (44.3)                              | 2266 (38.6)                                 | 26 (59.1)                     | 392 (55.6)                      |
| Female                     | 10 (16.9)                          | 141 (55.7)                              | 3606 (61.4)                                 | 18 (40.9)                     | 490 (44.4)                      |
| Missing                    | 13 (22.0)                          |                                         |                                             |                               |                                  |
| Birth year, range and 95% CI | Range 2010-2012                    | 95% CI 1982-2014                        | 95% CI 1958-1998                            | Range 1971-2013               | Range 2004-2013                  |
| Muscular dystrophy\(^b\), N| 689                                | 384                                     | 3305                                        |                               |                                  |
| Non-Hispanic black         | 16 (2.3)                           | 75 (19.5)                               | 805 (24.4)                                  |                               |                                  |
| Non-Hispanic white         | 379 (55.0)                         | 262 (68.2)                              | 1998 (60.5)                                 |                               |                                  |
| Hispanic and others        | 294 (42.7)                         | 47 (12.2)                               | 502 (15.2)                                  |                               |                                  |
| Male                       | 444 (64.4)                         | 258 (67.2)                              | 1707 (51.6)                                 |                               |                                  |
| Female                     | 245 (35.6)                         | 126 (32.8)                              | 1598 (48.4)                                 |                               |                                  |
| Birth year, range and mean (SD) | 1992-2011                          | 1973 (23)                               | 1969 (24)                                   |                               |                                  |
| Fragile X syndrome, N      | 6                                  | 141                                     | 795                                         |                               |                                  |
| Non-Hispanic black         | 57 (40.4)                          | 286 (36.0)                              |                                             |                               |                                  |
| Non-Hispanic white         | 66 (46.8)                          | 433 (54.5)                              |                                             |                               |                                  |
| Hispanic and others        | 18 (12.7)                          | 76 (9.6)                                |                                             |                               |                                  |
| Male                       | 88 (62.4)                          | 516 (64.9)                              |                                             |                               |                                  |
| Female                     | 53 (37.6)                          | 279 (35.1)                              |                                             |                               |                                  |
| Birth year, range and mean (SD) | 2007-2012                          | 1983 (19)                               | 1981 (19)                                   |                               |                                  |

\(^a\)Colorado did not implement an active case ascertainment system per se; instead, it supplemented the passive system with reascertentions and medical record reviews of all spina bifida cases and some muscular dystrophy cases.

\(^b\)Ellipses indicate that the cells contain less than 5 individuals; owing to confidentiality concerns, the exact number has been suppressed.

\(^c\)South Carolina and Colorado differed in the rigor of the active case ascertainment. Colorado, as part of Centers for Disease Control and Prevention’s Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), used a very thorough protocol for active case ascertainment. South Carolina was less intensive, recording fewer key variables. Both recorded counts for the 9 major forms of muscular dystrophy. Kansas did not collect data on Muscular Dystrophy or Fragile X.
Barriers to Implementation

The Colorado team reported no major problems implementing this project as they already actively ascertained or reascertained from passive reports the cases of muscular dystrophy and spina bifida. The limited time for this project (2 years) did not allow Colorado to officially request approval from the state legislature to change the age of reporting for fragile X syndrome from 3 to 10 years, as has been done with autism and fetal alcohol syndrome. Therefore, Colorado did not have any prevalent cases of fragile X syndrome to report and only 6 incident cases.

The major barrier to implementing a combined passive and active case ascertainment system for rare disorders in South Carolina is cost. Passive data sources are readily available and the active case ascertainment system is a natural extension of the ongoing DHEC Birth Defects Monitoring Program; however, the incremental cost of expanding active case ascertainment can be substantial. For this project, a full-time registered nurse with previous active case ascertainment experience was hired. The costs for the project included her salary and fringe benefits, training and travel, the customary clinical review of cases found, and the storage and protection of data. Finally, the utility of identifying and monitoring new cases needs to be justified with clear benefits for the patients and their caregivers.

In Kansas, the BDIS relies heavily on data from birth certificates with the age of 5 years being the limit for reporting genetic or congenital conditions [28,29]. The monitoring of conditions that are detectable long after birth under such constraints, such as fragile X syndrome and muscular dystrophy, could be challenging. After limiting the test to spina bifida, a major policy barrier surfaced. The Kansas law that created BDIS also made the records contained in this system strictly confidential and disclosable only by court order. Public disclosure is only allowed in summary or aggregated formats (law identified in Table 1); therefore, merging, matching, and analyzing the data had to be performed in situ by team members affiliated with the Kansas Department of Health and Environment.

To facilitate data sharing regarding medical records, the Kansas team contacted KFMC to perform medical record abstraction for this project. The KFMC has an established and credible relationship with health care providers in Kansas and recently partnered with the Kansas Department of Health and Environment to complete a record review project on their behalf. However, even with this established relationship and the state law, there was a limited response from providers to participate in the active component.

Discussion

This passive and active case ascertainment project was carried out to test the feasibility of establishing rare conditions passive and active case ascertainment systems for more than one condition at a time in states with varying levels of existing infrastructure. Having states at various stages of readiness for passive and active case ascertainment in this project allows for the identification of factors that may facilitate or impede the development of such systems.

The approach was to first assess the existing birth defects monitoring system in all 3 states, and then to identify additional processes that could be used to implement an ongoing rare conditions passive and active case ascertainment system. This project was not designed to compare active with passive case ascertainment; rather, it was designed to assess the feasibility of combining both types of case ascertainment systems to increase the yield of cases. The early steps for this project were successful: separately, all teams from the 3 states identified the connections to the data sources and determined the data elements to be collected. Together, the teams worked on the standardization of variable definitions to make the results comparable across systems and states. The definitions of the variables and their connections to the data sources were precisely documented to assure accurate replication.

This feasibility exercise helped us better understand the ways that states approach passive and active case ascertainment. Some states, like South Carolina and Colorado, have legal authority and ample experience monitoring birth defects. These 2 states use a variety of data sources for their passive and active case ascertainment systems, but active case ascertainment of rare diseases relies on obtaining funding through national programs.

Table 4. Prevalence rates of spina bifida, muscular dystrophy, and fragile X syndrome in the 3 states, based on reference population.

| Measure                        | South Carolina | Colorado | Kansas |
|--------------------------------|----------------|----------|--------|
| State and subarea population used for rate calculation (2014) | 4,832,482 state population for passive | 176,169 state for younger than 3 years | 2,904,021 state population for passive |
| Rate of spina bifida          | 1,170,249 for 5 countiesa for active case ascertainment | 3.35/10,000 younger than 3 years | 0.86/10,000 activeb |
| Rate of muscular dystrophy    | 2.16/10,000 active | 12.15/10,000 passive | 3.04/10,000 passive |
| Rate of fragile X syndrome    | 3.28/10,000 active | 6.84/10,000 passive | N/Ac |
|                               | 1.20/10,000 active | 1.65/10,000 passive | 0.01/10,000 |

a The 5 South Carolina counties for active case ascertainment are as follows: Berkeley, Dorchester, Charleston, Lexington, and Richland.
b Only 1 Kansas county was included in active case ascertainment.
c N/A: not applicable.
such as MD STARnet. In fact, after completion of this project, South Carolina was able to apply and get funding to join the national MD STARnet network. On the other hand, for other states, such as Kansas, the birth defects monitoring may have limited data sources and the implementation of a passive and active case ascertainment system to monitor more than one rare condition at once with both passive and active components would be a major challenge. Thus, as has been seen with other passive and active case ascertainment systems, funding through national networks or advocacy foundations appears to be the most viable approach to support the establishment of passive and active case ascertainment of rare conditions [35].

Because the purpose of the project was to assess the feasibility of establishing active and passive case ascertainment for rare conditions, we cannot guarantee the accuracy of the prevalence estimates; we have presented them here to provide reference for future work. Although the rates are not directly comparable because of state-to-state variations in data sources, prevalence of spina bifida was 2.16/10,000 people in South Carolina (active case ascertainment component), 3.35/10,000 in Colorado (passive case ascertainment component supplemented with case confirmations and clinical reviews), and 3.04/10,000 in Kansas (passive case ascertainment component; active case ascertainment resulted in limited follow-up). The prevalence of muscular dystrophy differed between South Carolina (3.28/10,000) and Colorado (1.29/10,000), although South Carolina used less rigorous criteria than the MD STARnet criteria and process [32] used by Colorado staff to define 9 forms of the condition. South Carolina was the only state able to test a combined passive and active case ascertainment approach for fragile X syndrome; the prevalence was 1.20/10,000 for active case ascertainment and 1.65/10,000 for passive case ascertainment.

The lessons learned have been valuable for the 3 states participating in this pilot project. Team participation and problem-solving approaches were excellent; however, state health departments will face obstacles if they seek to implement a combined passive and active case ascertainment system to simultaneously track rare disorders statewide. Although joint passive and active case ascertainment of rare disorders is feasible, only the passive component of case ascertainment seems to be readily available for use, even with limitations regarding data collection. The incorporation of the active component appears to be more of a long-term goal.

Acknowledgments

The authors would like to thank the following staff members of the Kansas Department of Health and Environment for their collaboration and support throughout this project: Greg Crawford, Joy Crevoiserat, Jamie Kim, and Heather Smith.

This research was supported by a cooperative agreement U01-DD000927 with the Centers for Disease Control and Prevention’s National Center on Birth Defects and Developmental Disabilities. The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, the South Carolina Revenue and Fiscal Affairs Office, the South Carolina Department of Health and Human Services, the South Carolina Public Employee Benefit Authority, the South Carolina Department of Disabilities and Special Needs, South Carolina Department of Health and Environmental Control, or the other agencies that participated in state-based passive and active case ascertainment.

Conflicts of Interest

None declared.

References

1. Hall H, Correa A, Yoon P, Braden C, Centers for Disease Control and Prevention. Lexicon, definitions, and conceptual framework for public health surveillance. MMWR Suppl 2012 Jul 27;61(3):10-14. [Medline: 22832991]
2. Mai C, Kirby R, Correa A, Rosenberg D, Petros M, Fagen M. Public Health Practice of Population-Based Birth Defects Surveillance Programs in the United States. J Public Health Manag Pract 2016;22(3):E1-E8. [doi: 10.1097/PHH.0000000000000221] [Medline: 25905668]
3. Salemi J, Tanner J, Sampat D, Anjohrin S, Correia J, Watkins S, et al. The Accuracy of Hospital Discharge Diagnosis Codes for Major Birth Defects: Evaluation of a Statewide Registry With Passive Case Ascertainment. J Public Health Manag Pract 2016;22(3):E9-E19. [doi: 10.1097/PHH.0000000000000291] [Medline: 26125321]
4. Schoellhorn J, Collins S. False positive reporting of Hirschsprung's disease in Alaska: an evaluation of Hirschsprung's disease surveillance, birth years 1996-2007. Birth Defects Res A Clin Mol Teratol 2009 Nov;85(11):914-919. [doi: 10.1002/bdra.20628] [Medline: 19777544]
5. Fox DJ, Druschel CM. Estimating prevalence of fetal alcohol syndrome (FAS): effectiveness of a passive birth defects registry system. Birth Defects Res A Clin Mol Teratol 2003 Sep;67(9):604-608. [doi: 10.1002/bdra.10108] [Medline: 14703781]
6. Honein MA, Paulozzi LJ. Birth defects surveillance: assessing the “gold standard”. Am J Public Health 1999 Aug;89(8):1238-1240. [Medline: 10432914]
7. Nsubuga P, White ME, Thacker SB, Anderson MA, Blount SB, Broome CV, et al. Public Health Surveillance: A Tool for Targeting and Monitoring Interventions. In: Jamison DT, Breman JG, Measham AR, editors. Disease Control Priorities in

http://pubhealth.jmir.org/2016/2/e151/
Developing Countries. 2nd edition. Washington, DC: The International Bank for Reconstruction and Development/The World Bank; 2006.
8. Centers for Disease Control and Prevention. Enhancing Surveillance. In: Manual for the surveillance of vaccine-preventable diseases. 5th edition. Atlanta: Centers for Disease Control Prevention; 2011.
9. Centers for Disease Control Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep 2009 Oct 16;58(40):1119-1122 [FREE Full text] [Medline: 19834452]
10. Bailey DB, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey. Pediatrics 2009 Aug;124(2):527-533. [doi: 10.1542/peds.2008-3992] [Medline: 19581269]
11. Salemi JL, Tanner JP, Kennedy S, Block S, Bailey M, Correia JA, et al. A comparison of two surveillance strategies for selected birth defects in Florida. Public Health Rep 2012;127(4):391-400 [FREE Full text] [Medline: 22753982]
12. Sandler AD. Children with spina bifida: key clinical issues. Pediatr Clin North Am 2010 Aug;57(4):879-892. [doi: 10.1016/j.pcl.2010.07.009] [Medline: 20883878]
13. Mathews TJ, Honein MA, Erickson JD. Spina bifida and anencephaly prevalence--United States, 1991-2001. MMWR Recomm Rep 2002 Sep 13;51(RR-13):9-11 [FREE Full text] [Medline: 12353510]
14. Parker S, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, National Birth Defects Prevention Network. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol 2010 Dec;88(12):1008-1016. [doi: 10.1002/bdra.20735] [Medline: 20878909]
15. Emery AE. The muscular dystrophies. Lancet 2002 Feb 23;359(9307):687-695. [doi: 10.1016/S0140-6736(02)07815-7] [Medline: 11879882]
16. National Institute of Child Health and Human Development. 2016. Spina Bifida Association of America URL: http://www.spinabifidaassociation.org [FREE Full text] [Medline: 1879882]
17. Romitti P, Zhu Y, Puzhankara S, James K, Nabukera S, Zamba G, et al. Prevalence of Duchenne and Becker Muscular Dystrophies in the United States. PEDIATRICS 2015;135(3):513-521.
18. Centers for Disease Control and Prevention. Facts about Muscular Dystrophy URL: http://www.cdc.gov/nicbddd/musculardystrophy/facts.html [accessed 2016-01-11] [WebCite Cache ID 6SSSUcpVU]
19. Crawford DC, Acuña JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3(5):359-371 [FREE Full text] [Medline: 11545690]
20. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 2002 Jun;12(3):278-283. [Medline: 12076670]
21. Saul RA, Friez M, Eaves K, Stapleton GA, Collins JS, Schwartz CE, et al. Fragile X syndrome detection in newborns-pilot study. Genet Med 2008 Oct;10(10):714-719. [doi: 10.1097/GIM.0b013e3181862a76] [Medline: 18813135]
22. Iosif A, Sciolla AF, Brahmbhatt K, Seritan AL. Caregiver Burden in Fragile X Families. Curr Psychiatry Rev 2013 Feb;17(1) [FREE Full text] [Medline: 2017458279]
23. Ouyang L, Grosse S, Riley C, Bolen J, Bishop E, Raspa M, et al. A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability. Res Dev Disabil 2014 Jul;35(7):1518-1527 [FREE Full text] [Medline: 24348279]
24. Centers for Disease Control Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep 2009 Oct 16;58(40):1119-1122 [FREE Full text] [Medline: 19834452]
25. Reichard et alJMIR PUBLIC HEALTH AND SURVEILLANCE
26. National Fragile X Foundation. FragileX. 2016. National Fragile X Foundation URL: https://www.nichd.nih.gov/health/topics/musculardys/conditioninfo/Pages/types.aspx [accessed 2016-01-11] [WebCite Cache ID 6SSSUcpVU]
27. Spina Bifida Association of America. Spina Bifida Association. 2016. Spina Bifida Association of America URL: http://spinabifidaassociation.org/ [accessed 2016-08-15] [WebCite Cache ID 6jme1eYVt]
28. National Center on Birth Defects Developmental Disabilities (CDC). State Birth Defects Surveillance Program Directory. Birth Defects Research (Part A): Clinical and Molecular Teratology 2011;91:1028-1149. [Medline: 17109399]
29. National Birth Defects Prevention Network. National Birth Defects Prevention Network. National Birth Defects Prevention Network: Birth Defects Surveillance, Research & Prevention URL: http://nbdpn.org/ [accessed 2016-08-15] [WebCite Cache ID 6jmi1eUiu3]
30. Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002 Jul;66(1):33-39. [doi: 10.1002/tera.10600] [Medline: 12115778]
31. Miller L, Romitti P, Cunniff C, Druschel C, Mathews KD, Meaney FJ, et al. The muscular dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol 2006 Nov;76(11):793-797. [doi: 10.1002/bdra.20279] [Medline: 17036307]
32. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Epi Info URL: http://wwwnc.cdc.gov/epiinfo/ [accessed 2016-01-11] [WebCite Cache ID 6eSTFMjtg]

33. SAS Institute, Inc. Procedures Guide: Statistical Procedures. Second Edition. In: Statistical Procedures. Second Edition. Cary, NC: SAS Institute Inc; 2013.

34. United States Census Bureau. 2014. QuickFacts URL: http://www.census.gov/quickfacts/table/PST045215/00,20173 [accessed 2016-01-11] [WebCite Cache ID 6eSTPh7Tr]

35. Woodruff RS, Pratt RH, Armstrong LR. The US National Tuberculosis Surveillance System: A Descriptive Assessment of the Completeness and Consistency of Data Reported from 2008 to 2012. JMIR Public Health and Surveillance 2015;1(2):e15. [doi: 10.2196/publichealth.4991] [Medline: 27227133]

Abbreviations

BDIS: birth defects information system  
CDC: Centers for Disease Control and Prevention  
CRCSN: Colorado Responds to Children with Special Needs  
DHEC: Department of Health and Environmental Control  
ICD-9: International Classification of Diseases, Ninth Revision,  
ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification  
ICD-10: International Classification of Diseases, Tenth Revision,  
IRB: institutional review board  
KFMC: Kansas Foundation for Medical Care  
MD STARnet: Muscular Dystrophy Surveillance, Tracking, and Research Network  
RFA: Revenue and Fiscal Affairs

©Amanda Reichard, Suzanne McDermott, Margaret Ruttenber, Joshua Mann, Michael G Smith, Julie Royer, Rodolfo Valdez. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 29.08.2016. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on http://publichealth.jmir.org, as well as this copyright and license information must be included.